| [1] |
Jemal A, Murray T, Samuels A, et al. Cancer statistics 2003[J]. CA Cancer J Clin, 2003, 53(1): 5-26.
|
| [2] |
Lakhani SR, Ellis IO, Schnitt SJ, et al. World Health Organization classification of tumors of the breast[M]. Lyon: IARC Press, 2012: 14.
|
| [3] |
Ding L, Kleer CG. Enhancer of zeste 2 as a marker of preneoplastic progression in the breast[J]. Cancer Res, 2006, 66(19): 9352-9355.
|
| [4] |
Bae WK, Hennighausen L. Canonical and non-canonical roles of the histone methyltransferase EZH2 in mammary development and cancer[J]. Mol Cell Endocrinol, 2014, 382(1): 593-597.
|
| [5] |
姚响芸，王萌，薛丽香．Polycomb蛋白复合体对细胞衰老的表观遗传学调控[J]．中国生物化学与分子生物学报，2012，28(4)：304-309.
|
| [6] |
Cavalli G. Molecular biology. EZH2 goes solo[J]. Science, 2012, 338(6113): 1430-1431.
|
| [7] |
Hobert O, Jallal B, Ullrich A. Interaction of Vav with ENX-1, a putative transcriptional regulator of homeobox gene expression[J]. Mol Cell Biol, 1996, 16(6): 3066-3073.
|
| [8] |
Cardoso C, Mignon C, Hetet G, et al. The human EZH2 gene: genomic organisation and revised mapping in 7q35 within the critical region for malignant myeloid disorders[J]. Eur J Hum Genet, 2000, 8(3): 174-180.
|
| [9] |
Deb G, Singh AK, Gupta S. EZH2: not EZHY (easy) to deal[J]. Mol Cancer Res, 2014, 12(5): 639-653.
|
| [10] |
Satijn DP, Otte AP. Polycomb group protein complexes: do different complexes regulate distinct target genes? [J]. Biochim Biophys Acta, 1999, 1447(1): 1-16.
|
| [11] |
Cao R, Zhang Y. The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3[J]. Curr Opin Genet Dev, 2004, 14(2): 155-164.
|
| [12] |
Visser HP, Gunster MJ, Kluin-Nelemans HC, et al. The polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma [J]. Br J Haematol, 2001, 112(4): 950-958.
|
| [13] |
Zhang H, Qi J, Reyes JM, et al. Oncogenic deregulation of EZH2 as an opportunity for targeted therapy in lung cancer[J]. Cancer Discov, 2016, 6(9): 1006-1021.
|
| [14] |
Cai MY, Tong ZT, Zheng F, et al. EZH2 protein: a promising immunomarker for the detection of hepatocellular carcinomas in liver needle biopsies[J]. Gut, 2011, 60(7): 967-976.
|
| [15] |
Ozen C, Yildiz G, Dagcan AT, et al. Genetics and epigenetics of liver cancer [J]. N Biotechnol, 2013, 30(4): 381-384.
|
| [16] |
Frankel AE, Liu X, Minna JD. Developing EZH2-targeted therapy for lung cancer[J]. Cancer Discov, 2016, 6(9): 949-952.
|
| [17] |
Martínez-Fernández M, Rubio C, Segovia C, et al. EZH2 in bladder cancer, a promising therapeutic target[J]. Int J Mol Sci, 2015, 16(11): 27 107-27 132.
|
| [18] |
Borbone E, Troncone G, Ferraro A, et al. Enhancer of zeste homolog 2 overexpression has a role in the development of anaplastic thyroid carcinomas[J]. J Clin Endocrinol Metab, 2011, 96(4): 1029-1038.
|
| [19] |
Jang SH, Lee JE, Oh MH, et al. High EZH2 protein expression is associated with poor overall survival in patients with luminal A breast cancer[J]. J Breast Cancer, 2016, 19(1): 53-60.
|
| [20] |
Guo S, Li X, Rohr J, et al. EZH2 overexpression in different immunophenotypes of breast carcinoma and association with clinicopathologic features[J]. Diagn Pathol, 2016, 11: 41.
|
| [21] |
Alford SH, Toy K, Merajver SD, et al. Increased risk for distant metastasis in patients with familial early-stage breast cancer and high EZH2 expression[J]. Breast Cancer Res Treat, 2012, 132(2): 429-437.
|
| [22] |
Gong Y, Huo L, Liu P, et al. Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome[J]. Cancer, 2011, 117(24): 5476-5484.
|
| [23] |
Collett K, Eide GE, Arnes J, et al. Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer[J]. Clin Cancer Res, 2006, 12(4): 1168-1174.
|
| [24] |
Wang X, Hu B, Shen H, et al. Clinical and prognostic relevance of EZH2 in breast cancer: A meta-analysis[J]. Biomed Pharmacother, 2015, 75: 218-225.
|
| [25] |
Knudsen ES, Dervishaj O, Kleer CG, et al. EZH2 and ALDH1 expression in ductal carcinoma in situ: complex association with recurrence and progression to invasive breast cancer[J]. Cell Cycle, 2013, 12(13): 2042-2050.
|
| [26] |
Wang L, Huang H. EZH2 takes the stage when BRCA1 loses[J]. Cell Cycle, 2013, 12(23): 3575-3576.
|
| [27] |
Zhao L, Zhang QY, Luan X, et al. Relationship between the expression of Notch1 and EZH2 and the prognosis of breast invasive ductal carcinoma[J]. Genet Mol Res, 2016, 15(1). doi: 10.4238/gmr.15017464. |
| [28] |
Yoo KH, Hennighausen L. EZH2 methyltransferase and H3K27 methylation in breast cancer[J]. Int J Biol Sci, 2012, 8(1): 59-65.
|
| [29] |
Li Z, Hou P, Fan D, et al. The degradation of EZH2 mediated by lncRNA ANCR attenuated the invasion and metastasis of breast cancer[J]. Cell Death Differ, 2017, 24(1): 59-71.
|
| [30] |
Jiang T, Wang Y, Zhou F, et al. Prognostic value of high EZH2 expression in patients with different types of cancer: a systematic review with meta-analysis[J]. Oncotarget, 2016, 7(4): 4584-4597.
|
| [31] |
严文君，冯爱强，张彦武，等．EZH2和CBX7在乳腺癌中的表达及其临床意义[J]．中国普通外科杂志，2014，23(11)：1512-1516.
|
| [32] |
江泽飞，许凤锐.2016年乳腺癌精准医学发展：困境与出路[J/CD]．中华乳腺病杂志(电子版)，2017，11(2)：65-68.
|